+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Herpes Zoster (Shingles) - Pipeline Review, H2 2019

  • ID: 4866548
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 67 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • CanSino Biologics Inc
  • CPL Biologicals Pvt Ltd
  • GC Pharma
  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • NAL Pharmaceuticals Ltd
  • MORE
Herpes Zoster (Shingles) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster - Pipeline Review, H2 2019, provides an overview of the Herpes Zoster (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Herpes Zoster (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 7, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Herpes Zoster (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Herpes Zoster (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Herpes Zoster (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • CanSino Biologics Inc
  • CPL Biologicals Pvt Ltd
  • GC Pharma
  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • NAL Pharmaceuticals Ltd
  • MORE
Introduction
Report Coverage
Herpes Zoster (Shingles) - Overview
Herpes Zoster (Shingles) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Herpes Zoster (Shingles) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
CPL Biologicals Pvt Ltd
DongKoo Bio & Pharma Co Ltd
GC Pharma
GeneOne Life Science Inc
GlaxoSmithKline Plc
NAL Pharmaceuticals Ltd
NanoViricides Inc
Shulov Innovative Science Ltd
Vaccitech Ltd
Vapogenix Inc
XBiotech Inc
Herpes Zoster (Shingles) - Drug Profiles
B-1006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSB-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLS-5100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVHHV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varicella zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTP-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Zoster (Shingles) - Dormant Projects
Herpes Zoster (Shingles) - Discontinued Products
Herpes Zoster (Shingles) - Product Development Milestones
Featured News & Press Releases
Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 - HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials
Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND
Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101
Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses
Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101
Aug 26, 2019: NanoViricides advancing rapidly towards first IND
Aug 05, 2019: NanoViricides reports its first drug candidate is on track with GLP safety/toxicology studies toward human clinical trials
Jul 10, 2019: Shingles vaccine safely prevents outbreaks among stem cell transplant patients
Jun 10, 2019: NanoViricides appoints Dr. Mark Day to its board of directors
Jun 03, 2019: NanoViricides has received favorable FDA comments on its pre-IND application for the lead drug candidate
May 24, 2019: China approves GSK’s shingles vaccine Shingrix in adults
May 13, 2019: NanoViricides announces completion of production of its lead candidate for upcoming GLP Tox package studies
Apr 24, 2019: GSK invests $100 million to expand long-term vaccine manufacturing capabilities in Hamilton, MT
Apr 16, 2019: NanoViricides submits pre-IND briefing documents to the US FDA
Apr 09, 2019: NanoViricides provides update on pre-IND meeting with the US FDA, GLP safety/toxicology studies to begin soon, multiple Kg scale drug production accomplished at its own facility
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Herpes Zoster (Shingles), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2019
Table 11: Herpes Zoster (Shingles) - Pipeline by CanSino Biologics Inc, H2 2019
Table 12: Herpes Zoster (Shingles) - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2019
Table 13: Herpes Zoster (Shingles) - Pipeline by CPL Biologicals Pvt Ltd, H2 2019
Table 14: Herpes Zoster (Shingles) - Pipeline by DongKoo Bio & Pharma Co Ltd, H2 2019
Table 15: Herpes Zoster (Shingles) - Pipeline by GC Pharma, H2 2019
Table 16: Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H2 2019
Table 17: Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 18: Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H2 2019
Table 19: Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H2 2019
Table 20: Herpes Zoster (Shingles) - Pipeline by Shulov Innovative Science Ltd, H2 2019
Table 21: Herpes Zoster (Shingles) - Pipeline by Vaccitech Ltd, H2 2019
Table 22: Herpes Zoster (Shingles) - Pipeline by Vapogenix Inc, H2 2019
Table 23: Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H2 2019
Table 24: Herpes Zoster (Shingles) - Dormant Projects, H2 2019
Table 25: Herpes Zoster (Shingles) - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Herpes Zoster (Shingles), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Beijing Minhai Biotechnology Co Ltd
  • CanSino Biologics Inc
  • Changchun Bcht Biotechnology Co Ltd
  • CPL Biologicals Pvt Ltd
  • DongKoo Bio & Pharma Co Ltd
  • GC Pharma
  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • NAL Pharmaceuticals Ltd
  • NanoViricides Inc
  • Shulov Innovative Science Ltd
  • Vaccitech Ltd
  • Vapogenix Inc
  • XBiotech Inc
Note: Product cover images may vary from those shown
Adroll
adroll